Aclaris Company Profile

What is the competitive landscape for ACLARIS

ACLARIS has one approved drug.

There are five US patents protecting ACLARIS drugs.

There are sixteen patent family members on ACLARIS drugs in sixteen countries and thirty-nine supplementary protection certificates in eleven countries.

Summary for Aclaris

International Patents:	16
US Patents:	5
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Aclaris

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	10,729,720		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	10,493,103		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	9,980,983
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	9,675,639		Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No	10,098,910		Y

Expired US Patents for Aclaris

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017	7,381,427

International Patents for Aclaris Drugs

Country	Patent Number	Estimated Expiration
Japan	6622217
Australia	2015249841
China	106659643
South Korea	20170029413
Poland	3134061
Singapore	11201608775X
Canada	2946568

Supplementary Protection Certificates for Aclaris Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2523731	202040016	Slovenia		PRODUCT NAME: OSILODROSTAT OR ITS PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING OSILODROSTAT DIHYDROGEN PHOSPHATE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1407; DATE OF NATIONAL AUTHORISATION: 20200109; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2523731	122020000026	Germany		PRODUCT NAME: OSILODROSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 20200109
2523731	CR 2020 00025	Denmark		PRODUCT NAME: OSILODROSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER OSILODROSTATDIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200113
3106463	11/2020	Austria		PRODUCT NAME: LAROTRECTINIB UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE LAROTRECTINIBSULFAT, EINSCHLIESSLICH LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923
2523731	2090024-7	Sweden		PRODUCT NAME: OSILODROSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING OSILODROSTAT DIHYDROGEN PHOSPHATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/19/1407, 2020-01-13; DEN 9 MAJ 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 2090024-7 1090021-5 1590035-0 1890009-2 1790067-1 2090007-2 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.
1968948	CR 2021 00044	Denmark		PRODUCT NAME: SELUMETINIB HYDROGENSULFAT OG SOLVATER OG ANHYDRID FORMER DERAF; REG. NO/DATE: EU/1/21/1552 20210619
0605697	SPC/GB01/008	United Kingdom		PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Aclaris